These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25416443)

  • 1. Comments on Li H et al. "A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma".
    Zhang Q; Li J; Liu F; Li Z
    Tumour Biol; 2015 Jan; 36(1):5-6. PubMed ID: 25416443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma.
    Li H; Zhang K; Liu LH; Ouyang Y; Bu J; Guo HB; Xiao T
    Tumour Biol; 2014 Jun; 35(6):5487-91. PubMed ID: 24577891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase 9 expression and survival of patients with osteosarcoma: a meta-analysis.
    Liu Y; Wang Y; Teng Z; Chen J; Li Y; Chen Z; Li Z; Zhang Z
    Eur J Cancer Care (Engl); 2017 Jan; 26(1):. PubMed ID: 26239566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questions about XY Wen et al. entitled "Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis".
    Liu F; Zhang Q
    Tumour Biol; 2015 Feb; 36(2):557-8. PubMed ID: 25663465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comments on Bu et al. "P16(INK₄a) overexpression and survival in osteosarcoma patients: a meta analysis".
    Yan MM; Ni JD
    Int J Clin Exp Pathol; 2015; 8(6):7617-8. PubMed ID: 26261680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: A meta-analysis of 16 studies.
    Zhou J; Liu T; Wang W
    Medicine (Baltimore); 2018 Nov; 97(44):e13051. PubMed ID: 30383677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma.
    Futamura N; Nishida Y; Urakawa H; Kozawa E; Ikuta K; Hamada S; Ishiguro N
    Tumour Biol; 2014 Jun; 35(6):5159-65. PubMed ID: 24481662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter regarding Wen X.Y. et al. entitled "Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis".
    Guo HB; Xiao T
    Tumour Biol; 2014 May; 35(5):5053. PubMed ID: 24449508
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter regarding Chen et al. entitled "a systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma".
    Liu LH; Li H; Xiao T
    Tumour Biol; 2014 Sep; 35(9):8535. PubMed ID: 25168371
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of MMP-2 expression and prognosis in osteosarcoma patients.
    Zhang M; Zhang X
    Int J Clin Exp Pathol; 2015; 8(11):14965-70. PubMed ID: 26823829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.
    Chen D; Zhang YJ; Zhu KW; Wang WC
    Tumour Biol; 2013 Jun; 34(3):1895-9. PubMed ID: 23589053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis.
    Wen X; Liu H; Yu K; Liu Y
    Tumour Biol; 2014 Jan; 35(1):845-8. PubMed ID: 24037915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter regarding Li JS et al. entitled "ERCC polymorphisms and prognosis of patients with osteosarcoma".
    Jian Y; Tian X; Li B; Zhou Z; Wu X
    Tumour Biol; 2015 May; 36(5):3195-6. PubMed ID: 25824708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comments on the article of Bu, et al entitled "P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis".
    Liu F; Zhou D; Zhang Q; Wang B
    Int J Clin Exp Pathol; 2015; 8(3):3384-5. PubMed ID: 26045875
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
    Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
    Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma.
    Wang YH; Han XD; Qiu Y; Xiong J; Yu Y; Wang B; Zhu ZZ; Qian BP; Chen YX; Wang SF; Shi HF; Sun X
    J Surg Oncol; 2012 Mar; 105(3):235-43. PubMed ID: 21866554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma.
    Felx M; Guyot MC; Isler M; Turcotte RE; Doyon J; Khatib AM; Leclerc S; Moreau A; Moldovan F
    Clin Sci (Lond); 2006 Jun; 110(6):645-54. PubMed ID: 16417466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances.
    Huang H
    Sensors (Basel); 2018 Sep; 18(10):. PubMed ID: 30262739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: review and meta-analysis.
    Wang J; Shi Q; Yuan TX; Song QL; Zhang Y; Wei Q; Zhou L; Luo J; Zuo G; Tang M; He TC; Weng Y
    Clin Chim Acta; 2014 Jun; 433():225-31. PubMed ID: 24704305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucosamine sulfate suppresses the expression of matrix metalloproteinase-3 in osteosarcoma cells in vitro.
    Pohlig F; Ulrich J; Lenze U; Mühlhofer HM; Harrasser N; Suren C; Schauwecker J; Mayer-Kuckuk P; von Eisenhart-Rothe R
    BMC Complement Altern Med; 2016 Aug; 16(1):313. PubMed ID: 27562075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.